Philip A. Sutera

Philip A. Sutera, M.D., is an Assistant Professor in the Department of Radiation Oncology at the University of Rochester School of Medicine and Dentistry. He practices at the Wilmot Cancer Institute and is affiliated with the University of Rochester Medical Faculty Group (URMFG) and Accountable Health Partners (AHP). His clinical and research focus spans advanced radiation therapies for prostate and bladder cancer, with particular emphasis on oligometastatic disease and genomic biomarkers.

• MD, University of Pittsburgh School of Medicine (2019)
• Residency, Radiation Oncology, Johns Hopkins University School of Medicine (2020-2024)
• Internship, Internal Medicine, Allegheny General Hospital (2019-2020)

Dr. Sutera's research integrates machine learning, radiomics, and genomic profiling to optimize radiation therapy outcomes. His work has been published in leading journals like Radiotherapy and Oncology and Clinical Cancer Research, with a focus on PSMA PET imaging, metastasis-free survival prediction, and pathway-based biomarkers in castration-sensitive prostate cancer.

His recent publications highlight trends in artificial intelligence applications for prognostic modeling, genomic determinants of therapy response, and comparative analyses of imaging modalities (PSMA PET/CT vs conventional imaging) in oligometastatic disease. Recurring themes include stereotactic ablative radiotherapy (SABR), immune cell infiltration in chemoradiation, and mitochondrial dysfunction in radiation-induced apoptosis.

• ASTRO Annual Meeting Abstract Award (2024)
• ASCO Conquer Cancer Merit Award (2024)
• American Radium Society Travel Grant (2023)
• Bert and Sally O'Malley Award (2019)
...

Dr. Sutera's clinical work involves stereotactic body radiation therapy (SBRT) for pancreatic carcinoma and salvage radiosurgery for recurrent gliomas. His research extends to DNA damage mechanisms in radiation therapy and proteomic responses to novel agents like Dinaciclib and YM155. He collaborates with teams in the STOMP and ORIOLE trials and contributes to evolving definitions of disease burden in metastatic castration-sensitive prostate cancer.